[go: up one dir, main page]

MX2010005226A - Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo. - Google Patents

Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.

Info

Publication number
MX2010005226A
MX2010005226A MX2010005226A MX2010005226A MX2010005226A MX 2010005226 A MX2010005226 A MX 2010005226A MX 2010005226 A MX2010005226 A MX 2010005226A MX 2010005226 A MX2010005226 A MX 2010005226A MX 2010005226 A MX2010005226 A MX 2010005226A
Authority
MX
Mexico
Prior art keywords
hcv ns5b
ns5b inhibitors
cyclopropyl fused
fused indolobenzazepine
indolobenzazepine hcv
Prior art date
Application number
MX2010005226A
Other languages
English (en)
Inventor
Piyasena Hewawasam
Min Ding
John A Bender
Robert G Gentles
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2010005226A publication Critical patent/MX2010005226A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención abarca compuestos de la fórmula (I) así como composiciones y métodos para usar los compuestos. Los compuestos tienen actividad contra virus de la hepatitis C (HCV) y son útiles en el tratamiento de aquellos infectados con HCV.
MX2010005226A 2007-11-20 2007-11-20 Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo. MX2010005226A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/085183 WO2009067108A1 (en) 2007-11-20 2007-11-20 Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Publications (1)

Publication Number Publication Date
MX2010005226A true MX2010005226A (es) 2010-05-27

Family

ID=40010653

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005226A MX2010005226A (es) 2007-11-20 2007-11-20 Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.

Country Status (14)

Country Link
EP (1) EP2209789B1 (es)
JP (1) JP5416710B2 (es)
KR (1) KR20100108341A (es)
CN (1) CN101918410B (es)
AT (1) ATE533771T1 (es)
AU (1) AU2007361468A1 (es)
CY (1) CY1112699T1 (es)
DK (1) DK2209789T3 (es)
ES (1) ES2375065T3 (es)
MX (1) MX2010005226A (es)
PL (1) PL2209789T3 (es)
PT (1) PT2209789E (es)
SI (1) SI2209789T1 (es)
WO (1) WO2009067108A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
MX2010010235A (es) 2008-03-27 2010-10-05 Bristol Myers Squibb Co Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.
JP2011515486A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2014014885A1 (en) * 2012-07-18 2014-01-23 Bristol-Myers Squibb Company Novel methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3-methoxy-5a-((1 r,5s) -3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US11590239B2 (en) 2016-02-08 2023-02-28 Synaffix B.V. Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates
WO2017137456A1 (en) 2016-02-08 2017-08-17 Synaffix B.V. Bioconjugates containing sulfamide linkers for use in treatment
US10874746B2 (en) * 2016-02-08 2020-12-29 Synaffix B.V. Sulfamide linkers for use in bioconjugates
AU2017233739A1 (en) 2016-03-15 2018-09-20 Bayer Cropscience Aktiengesellschaft Substituted sulfonyl amides for controlling animal pests
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
BR112022008883A2 (pt) 2019-11-07 2022-08-23 Bayer Ag Sulfonil amidas substituídas para controle de pragas animais
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100387580C (zh) * 1997-09-29 2008-05-14 明治制果株式会社 三环三唑并苯并氮杂䓬衍生物、用于制备该衍生物的方法和抗变态反应剂
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ES2343914T3 (es) * 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
CN103224506A (zh) * 2006-12-20 2013-07-31 P.安杰莱蒂分子生物学研究所 抗病毒的吲哚
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2121694B1 (en) * 2007-03-13 2014-07-16 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
PL2209789T3 (pl) 2012-04-30
JP2011503229A (ja) 2011-01-27
PT2209789E (pt) 2012-01-16
CY1112699T1 (el) 2016-02-10
DK2209789T3 (da) 2012-03-05
CN101918410B (zh) 2013-02-27
KR20100108341A (ko) 2010-10-06
EP2209789B1 (en) 2011-11-16
AU2007361468A1 (en) 2009-05-28
EP2209789A1 (en) 2010-07-28
JP5416710B2 (ja) 2014-02-12
CN101918410A (zh) 2010-12-15
SI2209789T1 (sl) 2012-06-29
WO2009067108A1 (en) 2009-05-28
ATE533771T1 (de) 2011-12-15
ES2375065T3 (es) 2012-02-24

Similar Documents

Publication Publication Date Title
PL2209789T3 (pl) Skondensowane z cyklopropylem indolobenzoazepinowe inhibitory NS5B HCV
PL1987038T3 (pl) Inhibitory HCV NS5B
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
TW200745035A (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
TW200745120A (en) Indolobenzazepine HCV NS5B inhibitors
MX2011009644A (es) Inhibidores del virus de la hepatitis c.
MY152070A (en) Macrocyclic quinxaline compounds as hcv ns3 protease inhibitors
MX2010001416A (es) Compuesto para el tratamiento de la hepatitis c.
MX2013002927A (es) Inhibidores del virus de la hepatitis c.
ATE522532T1 (de) Verbindungen zur behandlung von hepatitis c
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
EA201270555A1 (ru) Комбинации ингибиторов вируса гепатита с
MX2011006631A (es) Inhibidores de proteasa ns3 del virus hcv.
MX2009004556A (es) Inhibidores de la proteasa ns3 del hcv.
ATE494291T1 (de) Verbindungen zur behandlung von hepatitis c
EA200802346A1 (ru) Циклопропилконденсированные индолобензазепиновые ингибиторы белка ns5b вируса гепатита с
MX2012004032A (es) Compuestos para el tratamiento de hepatitis c.
MX337050B (es) Compuestos 4'-azido-nucleósidos como anti-vhc.
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
ATE551343T1 (de) Tetracyclische verbindungen zur behandlung von hepatitis c
ATE505473T1 (de) Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c
MX2013004464A (es) Inhibidores de polimerasa viral.
MX2010010061A (es) Compuestos para el tratamiento de hepatitis c.
MX2010010235A (es) Inhibidores de ns5b de virus de la hepatitis c de indolobenzadiazepina fusionados a pirrolidina.

Legal Events

Date Code Title Description
FG Grant or registration